Tag: Atrial Fibrillation
Apixaban Compared to Rivaroxaban for A-Fib and Valvular Heart Disease
Risks for ischemic stroke or systemic embolism, bleeding reduced with apixaban versus rivaroxaban for atrial fibrillation and valvular heart disease
ECG Anomalies May Affect Accuracy of Smartwatch A-Fib Diagnosis
Nondiagnostic tracings and false positives seen with smartwatch algorithm detection of AF in those with cardiac anomalies
New-Onset A-Fib Profiled in Patients Hospitalized With COVID-19
New-onset atrial fibrillation identified in about one in 20 patients hospitalized with COVID-19
A-Fib Risk Higher in Women After Adjusting for Height, Size
Risk for atrial fibrillation is greater in women than men after adjusting for height, height and weight, or body surface area
Early Rhythm Control May Benefit Low-Risk A-Fib Patients
Early rhythm control linked to reduced risk for cardiovascular complications for those meeting, not meeting eligibility for EAST-AFNET 4 trial
Left Atrial Appendage Occlusion Favored for Some A-Fib Patients
Baseline risks for stroke, bleeding determine whether LAAO is preferred to anticoagulants for a-fib patients with high bleeding risk
Formulary Restrictions May Worsen Atrial Fibrillation Outcomes
Risk for adverse health outcomes higher for patients with Medicare Part D plans limiting access to non-vitamin K antagonist oral anticoagulants
Screening for A-Fib Using Wearable Devices May Be Cost-Effective
Wearable devices are cost-effective compared with no screening or screening using traditional methods
Premature Menopause May Increase Risk for Heart Failure, A-Fib
Ages 45 to 49, 40 to 44, younger than 40 years versus 50 years or older at menopause associated with increased risks for heart failure, atrial fibrillation
Migraine With Aura ID’d as Independent Risk Factor for A-Fib
Novel AI ECG algorithm shows patients with MwA have higher AF prediction model output, indicating higher probability of atrial fibrillation
